{"id":"https://openalex.org/W7225320786","doi":"https://doi.org/10.3389/fphar.2026.2007309","title":"Surufatinib and camrelizumab plus nab-paclitaxel\u2013gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study","display_name":"Surufatinib and camrelizumab plus nab-paclitaxel\u2013gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225320786","doi":"https://doi.org/10.3389/fphar.2026.2007309"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.2007309","doi":"https://doi.org/10.3389/fphar.2026.2007309","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2007309","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2007309/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2007309/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040018747","display_name":"Yudong Yuan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802573037","display_name":"Tianjin Medical University Cancer Institute and Hospital","ror":"https://ror.org/0152hn881","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802573037"]},{"id":"https://openalex.org/I4210121984","display_name":"Shengli Oilfield Central Hospital","ror":"https://ror.org/035wt7p80","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210121984"]},{"id":"https://openalex.org/I5740404","display_name":"Tianjin Medical University","ror":"https://ror.org/02mh8wx89","country_code":"CN","type":"education","lineage":["https://openalex.org/I5740404"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Yudong Yuan","raw_affiliation_strings":["Shengli Oilfield Central Hospital","Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shengli Oilfield Central Hospital","institution_ids":["https://openalex.org/I4210121984"]},{"raw_affiliation_string":"Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer","institution_ids":["https://openalex.org/I2802573037","https://openalex.org/I5740404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028212636","display_name":"Dongmei Zhang","orcid":"https://orcid.org/0000-0003-2378-2458","observed_orcids":["https://orcid.org/0000-0003-2378-2458","https://orcid.org/0009-0003-3625-7860"]},"institutions":[{"id":"https://openalex.org/I2802573037","display_name":"Tianjin Medical University Cancer Institute and Hospital","ror":"https://ror.org/0152hn881","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802573037"]},{"id":"https://openalex.org/I4210121984","display_name":"Shengli Oilfield Central Hospital","ror":"https://ror.org/035wt7p80","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210121984"]},{"id":"https://openalex.org/I5740404","display_name":"Tianjin Medical University","ror":"https://ror.org/02mh8wx89","country_code":"CN","type":"education","lineage":["https://openalex.org/I5740404"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Dongdong Zhang","raw_affiliation_strings":["Shengli Oilfield Central Hospital","Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shengli Oilfield Central Hospital","institution_ids":["https://openalex.org/I4210121984"]},{"raw_affiliation_string":"Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer","institution_ids":["https://openalex.org/I2802573037","https://openalex.org/I5740404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5127783454","display_name":"Yuying Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121984","display_name":"Shengli Oilfield Central Hospital","ror":"https://ror.org/035wt7p80","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210121984"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yuying Li","raw_affiliation_strings":["Shengli Oilfield Central Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shengli Oilfield Central Hospital","institution_ids":["https://openalex.org/I4210121984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5121097781","display_name":"Chongbiao Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802573037","display_name":"Tianjin Medical University Cancer Institute and Hospital","ror":"https://ror.org/0152hn881","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802573037"]},{"id":"https://openalex.org/I5740404","display_name":"Tianjin Medical University","ror":"https://ror.org/02mh8wx89","country_code":"CN","type":"education","lineage":["https://openalex.org/I5740404"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Chongbiao Huang","raw_affiliation_strings":["Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer","institution_ids":["https://openalex.org/I2802573037","https://openalex.org/I5740404"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5040018747","https://openalex.org/A5121097781"],"corresponding_institution_ids":["https://openalex.org/I2802573037","https://openalex.org/I4210121984","https://openalex.org/I5740404"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/surufatinib","display_name":"surufatinib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/camrelizumab","display_name":"camrelizumab","score":1.0},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9350000023841858},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":1.0},{"id":"https://openalex.org/keywords/metastatic-pancreatic-ductal-adenocarcinoma","display_name":"metastatic pancreatic ductal adenocarcinoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9259999990463257},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.6439999938011169},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.5690000057220459},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7609999775886536},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8629999756813049},{"id":"https://openalex.org/keywords/ca19-9","display_name":"CA19-9","score":0.7649999856948853},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.5860000252723694},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.41600000858306885},{"id":"https://openalex.org/keywords/relative-dose-intensity","display_name":"relative dose intensity","score":0.6919999718666077},{"id":"https://openalex.org/keywords/microsatellite-stability","display_name":"microsatellite stable","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9150999784469604},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6970999836921692},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.6934999823570251},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6926000118255615},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.635699987411499},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5202999711036682},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5099999904632568},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4738999903202057},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4465000033378601},{"id":"https://openalex.org/C2992026798","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic ductal adenocarcinoma","level":4,"score":0.4083000123500824},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.3555999994277954},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3402999937534332},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32989999651908875},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.32249999046325684},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.31139999628067017},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.30559998750686646},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.302700012922287},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.30160000920295715},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.2946999967098236},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.29089999198913574},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.2831000089645386},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.28299999237060547},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2815000116825104},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.2685999870300293},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.2619999945163727}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fphar.2026.2007309","doi":"https://doi.org/10.3389/fphar.2026.2007309","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2007309","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2007309/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:5d2b1c80bf1f4a0791c21fdcc7e75ff0","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/5d2b1c80bf1f4a0791c21fdcc7e75ff0","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.2007309","doi":"https://doi.org/10.3389/fphar.2026.2007309","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2007309","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2007309/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225320786.pdf","grobid_xml":"https://content.openalex.org/works/W7225320786.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1940241680","https://openalex.org/W1971211622","https://openalex.org/W1977247044","https://openalex.org/W1988262403","https://openalex.org/W1997944395","https://openalex.org/W2019607817","https://openalex.org/W2043991982","https://openalex.org/W2072013249","https://openalex.org/W2086834665","https://openalex.org/W2128095147","https://openalex.org/W2151253787","https://openalex.org/W2156906256","https://openalex.org/W2165480504","https://openalex.org/W2264767503","https://openalex.org/W2285607949","https://openalex.org/W2469223980","https://openalex.org/W2583252578","https://openalex.org/W2605792367","https://openalex.org/W2777989556","https://openalex.org/W2793938850","https://openalex.org/W2959096163","https://openalex.org/W2984359187","https://openalex.org/W3087238097","https://openalex.org/W3087682866","https://openalex.org/W3207013188","https://openalex.org/W4282037063","https://openalex.org/W4293109639","https://openalex.org/W4310466207","https://openalex.org/W4386614978","https://openalex.org/W4399379463","https://openalex.org/W4410510198","https://openalex.org/W4415091053","https://openalex.org/W7161034127","https://openalex.org/W7169757219"],"related_works":["https://openalex.org/W4415091053","https://openalex.org/W4410817085","https://openalex.org/W7164814397","https://openalex.org/W4410510198","https://openalex.org/W4391096787","https://openalex.org/W4379283520","https://openalex.org/W7154712810","https://openalex.org/W4391091449","https://openalex.org/W7162531590","https://openalex.org/W4410815986"],"abstract_inverted_index":{"Background":[0],"Surufatinib":[1],"targets":[2],"angiogenic":[3],"and":[4,25,47,66,84,108,151,162,192,217,242,263],"myeloid":[5],"signaling":[6],"pathways":[7],"that":[8],"may":[9],"contribute":[10],"to":[11,13,28,260],"resistance":[12],"immune":[14],"checkpoint":[15],"blockade":[16],"in":[17,31,170,188,197,230],"pancreatic":[18],"ductal":[19],"adenocarcinoma":[20],"(PDAC).":[21],"We":[22],"evaluated":[23],"surufatinib":[24],"camrelizumab":[26],"added":[27],"nab-paclitaxel\u2013gemcitabine":[29],"(AG)":[30],"routine":[32],"first-line":[33,57],"treatment.":[34],"Methods":[35],"This":[36],"exploratory":[37],"single-center":[38],"retrospective":[39],"cohort":[40],"included":[41],"132":[42],"patients":[43,175],"with":[44,105,111,176,239,258],"metastatic":[45],"PDAC":[46],"documented":[48],"proficient":[49],"mismatch":[50],"repair":[51],"or":[52,250],"microsatellite":[53],"stability":[54],"who":[55],"started":[56],"treatment":[58,85],"during":[59],"2022\u20132025.":[60],"Forty-four":[61],"received":[62,68],"surufatinib\u2013camrelizumab":[63],"plus":[64,235],"AG":[65,112,236],"88":[67],"AG.":[69],"Real-world":[70],"progression-free":[71],"survival":[72,79],"(rwPFS)":[73],"was":[74,102,121,133,205,227,237],"the":[75,106,117,171],"primary":[76],"outcome.":[77],"Overall":[78],"(OS),":[80],"tumor":[81],"response,":[82],"safety,":[83],"delivery":[86],"were":[87,92,149,160],"also":[88],"assessed.":[89],"Survival":[90],"associations":[91],"adjusted":[93,118,248],"for":[94,209,214,219],"clinically":[95],"selected":[96],"baseline":[97],"factors.":[98],"Results":[99],"Median":[100,131,201,221],"rwPFS":[101,249],"6.3":[103],"months":[104,110,137],"combination":[107,172],"4.1":[109],"(log-rank":[113],"P":[114,128],"=":[115,129,155,165,181],"0.021);":[116],"hazard":[119,139],"ratio":[120],"0.73":[122],"(95%":[123],"confidence":[124],"interval":[125],"[CI],":[126],"0.47\u20131.12;":[127],"0.152).":[130],"OS":[132,251],"9.7":[134],"versus":[135,190,199,207],"8.4":[136],"(adjusted":[138],"ratio,":[140],"0.89;":[141],"95%":[142],"CI,":[143],"0.57\u20131.38).":[144],"Unconfirmed":[145],"objective":[146],"response":[147,158,244],"rates":[148,159],"45.5%":[150],"19.3%,":[152],"respectively":[153],"(P":[154,164,180],"0.004).":[156],"Confirmed":[157],"38.6%":[161],"15.9%":[163],"0.005).":[166],"CA19-9":[167],"declined":[168],"more":[169],"group":[173],"among":[174],"eligible":[177],"paired":[178],"measurements":[179],"0.032).":[182],"Grade":[183],"\u22653":[184],"adverse":[185],"events":[186],"occurred":[187,196],"47.7%":[189],"34.1%,":[191],"toxicity-related":[193],"permanent":[194],"discontinuation":[195],"18.2%":[198],"11.4%.":[200],"relative":[202],"dose":[203,261],"intensity":[204],"87.0%":[206],"87.9%":[208],"both":[210],"chemotherapy":[211],"agents,":[212],"79.1%":[213],"prescribed":[215],"surufatinib,":[216],"100.0%":[218],"camrelizumab.":[220],"follow-up":[222],"by":[223],"reverse":[224],"Kaplan\u2013Meier":[225],"estimation":[226],"not":[228],"estimable":[229],"either":[231],"group.":[232],"Conclusion":[233],"Surufatinib\u2013camrelizumab":[234],"associated":[238],"higher":[240],"unconfirmed":[241],"confirmed":[243],"rates,":[245],"without":[246],"significant":[247],"differences.":[252],"The":[253],"findings":[254],"support":[255],"prospective":[256],"evaluation":[257],"attention":[259],"optimization":[262],"toxicity":[264],"management.":[265]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-11-06T00:00:00"}